

Atty. Dkt. No. 034536-0928

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

- 1-16. (Canceled)
17. (Currently amended) An isolated, ~~enriched or purified~~ antibody or antibody fragment having specific binding affinity to the an AUR1 and/or AUR2 polypeptide encoded by SEQ ID NO: 3 or SEQ ID NO: 4.
18. (Currently amended) A hybridoma which produces an antibody having specific binding affinity to the an AUR1 and/or AUR2 polypeptide encoded by SEQ ID NO: 3 or SEQ ID NO: 4.
- 19-28. (Canceled)
29. (Currently amended) An antibody or antibody fragment according to claim 17, having specific binding affinity for the N-terminal domain of said AUR1 and/or AUR2 polypeptide.
30. (Canceled)
31. (Currently amended) An antibody or antibody fragment according to claim 17, having specific binding affinity for the catalytic domain of said AUR1 and/or AUR2 polypeptide.
32. (Canceled)
33. (Currently amended) An antibody or antibody fragment according to claim 17, having specific binding affinity for the C-terminal domain of said AUR1 and/or AUR2 polypeptide.
34. (Canceled)
35. (Currently amended) An antibody or antibody fragment according to claim 17 that is monoclonal.

Atty. Dkt. No. 034536-0928

36. (Previously presented) An antibody or antibody fragment according to claim 17 that is humanized.
37. (Currently amended) The hybridoma of claim 18, wherein said antibody has specific binding affinity for the N-terminal domain of said AUR1 and/or AUR2 polypeptide.
38. (Canceled)
39. (Currently amended) The hybridoma of claim 18, wherein said antibody has specific binding affinity for the catalytic domain of said AUR1 and/or AUR2 polypeptide.
40. (Canceled)
41. (Currently amended) The hybridoma of claim 18, wherein said antibody has specific binding affinity for the C-terminal domain of said AUR1 and/or AUR2 polypeptide.
42. (Canceled)